News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
634,529 Results
Type
Article (20253)
Company Profile (201)
Press Release (614476)
Multimedia
Podcasts (55)
Webinars (13)
Section
Business (211377)
Career Advice (707)
Deals (31879)
Drug Delivery (48)
Drug Development (64203)
Employer Resources (57)
FDA (13381)
Job Trends (11683)
News (299629)
Policy (23108)
Tag
2027 BioCapital Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (1507)
Accelerated approval (29)
ADA (26)
Adcomms (2)
Allergies (156)
Alliances (47159)
ALS (143)
Alzheimer's disease (1281)
Antibody-drug conjugate (ADC) (399)
Approvals (14050)
Artificial intelligence (685)
ASCO (204)
Autoimmune disease (265)
Automation (61)
Bankruptcy (297)
Best Places to Work (9328)
BIO (51)
BIOSECURE Act (7)
Biosimilars (129)
Biotechnology (137)
Bladder cancer (163)
Brain cancer (50)
Breast cancer (620)
Cancer (4829)
Cardiovascular disease (317)
Career advice (616)
Career pathing (12)
CAR-T (306)
CDC (12)
Celiac Disease (1)
Cell therapy (800)
Cervical cancer (46)
Clinical research (56902)
Collaboration (2001)
Company closure (1)
Compensation (1436)
Complete response letters (38)
COVID-19 (1498)
CRISPR (114)
C-suite (1050)
Cystic fibrosis (112)
Data (7011)
Decentralized trials (2)
Denatured (28)
Depression (121)
Dermatology (73)
Diabetes (448)
Diagnostics (6508)
Digital health (64)
Diversity (7)
Diversity, equity & inclusion (12)
Drug discovery (298)
Drug pricing (24)
Drug shortages (7)
Duchenne muscular dystrophy (195)
Earnings (83869)
Editorial (11)
Employer branding (9)
Employer resources (53)
Events (108252)
Executive appointments (981)
FDA (16820)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (17)
Frontotemporal dementia (29)
Funding (1525)
Gene editing (237)
Generative AI (50)
Gene therapy (571)
GLP-1 (496)
Government (1826)
Grass and pollen (4)
Guidances (351)
Healthcare (14421)
Hematology (123)
HIV (66)
Huntington's disease (28)
IgA nephropathy (74)
Immunology and inflammation (133)
Immuno-oncology (70)
Indications (185)
Infectious disease (1774)
Inflammatory bowel disease (160)
Inflation Reduction Act (6)
Influenza (125)
Intellectual property (304)
Interviews (84)
IPO (14964)
IRA (10)
Job creations (2752)
Job search strategy (552)
JPM (22)
Kidney cancer (17)
Labor market (27)
Layoffs (175)
Leadership (8)
Legal (6032)
Liver cancer (71)
Longevity (28)
Lung cancer (590)
Lymphoma (336)
Machine learning (56)
Management (20)
Manufacturing (933)
Marketing (6)
MASH (138)
Medical device (13667)
Medtech (13865)
Mergers & acquisitions (18176)
Metabolic disorders (919)
mRNA (191)
Multiple sclerosis (135)
NASH (7)
Neurodegenerative disease (324)
Neuropsychiatric disorders (52)
Neuroscience (2421)
NextGen: Class of 2026 (5049)
Non-profit (2024)
Now hiring (17)
Obesity (301)
Opinion (118)
Ovarian cancer (190)
Pain (207)
Pancreatic cancer (272)
Parkinson's disease (293)
Partnered (24)
Patents (578)
Patient recruitment (657)
Peanut (61)
People (53044)
Pharmaceutical (40)
Pharmacy benefit managers (12)
Phase 1 (18926)
Phase 2 (25362)
Phase 3 (17132)
Pipeline (8612)
Policy (78)
Postmarket research (1729)
Preclinical (8169)
Press Release (69)
Prostate cancer (264)
Psychedelics (10)
Radiopharmaceuticals (310)
Rare diseases (748)
Real estate (4879)
Recruiting (25)
Regulatory (19359)
Reports (22)
Research institute (1574)
Resumes & cover letters (107)
Rett syndrome (44)
RNA editing (18)
RSV (64)
Schizophrenia (115)
Series A (270)
Series B (190)
Service/supplier (5)
Sickle cell disease (76)
Special edition (1)
Spinal muscular atrophy (105)
Sponsored (25)
Startups (3308)
State (2)
Stomach cancer (4)
Supply chain (77)
Tariffs (11)
The Weekly (25)
Vaccines (695)
Venture capital (64)
Weight loss (110)
Women's health (102)
Worklife (4)
Date
Today (80)
Last 7 days (370)
Last 30 days (1559)
Last 365 days (25194)
2026 (14228)
2025 (25192)
2024 (30115)
2023 (34723)
2022 (45194)
2021 (48664)
2020 (45649)
2019 (36380)
2018 (27258)
2017 (27200)
2016 (26234)
2015 (32733)
2014 (27768)
2013 (23737)
2012 (25694)
2011 (26031)
2010 (24896)
Location
Africa (450)
Alabama (83)
Alaska (6)
Arizona (345)
Arkansas (16)
Asia (33467)
Australia (5224)
California (13095)
Canada (3598)
China (1054)
Colorado (577)
Connecticut (508)
Delaware (291)
Europe (63826)
Florida (1966)
Georgia (426)
Hawaii (3)
Idaho (60)
Illinois (998)
India (75)
Indiana (431)
Iowa (19)
Japan (554)
Kansas (122)
Kentucky (45)
Louisiana (39)
Maine (38)
Maryland (1454)
Massachusetts (9200)
Michigan (389)
Minnesota (722)
Mississippi (6)
Missouri (141)
Montana (31)
Nebraska (19)
Nevada (127)
New Hampshire (89)
New Jersey (3079)
New Mexico (25)
New York (3336)
North Carolina (1595)
North Dakota (10)
Northern California (6466)
Ohio (369)
Oklahoma (22)
Oregon (26)
Pennsylvania (2536)
Puerto Rico (26)
Rhode Island (48)
South America (726)
South Carolina (89)
South Dakota (1)
Southern California (5378)
Tennessee (187)
Texas (2142)
United States (44974)
Utah (404)
Vermont (2)
Virginia (226)
Washington D.C. (52)
Washington State (1060)
West Virginia (3)
Wisconsin (137)
Wyoming (1)
634,529 Results for "invivoscribe technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification
March 26, 2026
·
3 min read
Press Releases
Invivoscribe Announces the PrepQuant™ System, an Integrated Sample Preparation Platform that Standardizes and Streamlines Pre-Analytical Workflows
April 15, 2026
·
3 min read
Press Releases
Invivoscribe’s LabPMM Gains New York State Approval for the FLT3 ITD MRD Assay
April 22, 2025
·
2 min read
Press Releases
Invivoscribe Expands Flow Cytometry Services to Accelerate CAR-T Immunotherapy Development and Regulatory Readiness with the Initiation of CERo Therapeutics Phase 1 Clinical Trial
July 8, 2025
·
4 min read
Press Releases
BioStem Technologies Announces Issuance of Four U.S. Design Patents Covering Fenestrated Human Placental Allograft Technologies
July 8, 2026
·
3 min read
Press Releases
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
June 11, 2026
·
5 min read
Press Releases
Augurex Named ADLM 2026 Disruptive Technology Award Finalist
• Augurex’s SPINEstat® (Anti-14-3-3eta Multiplex for axial spondyloarthritis) test has been selected as a finalist in the ADLM 2026 Disruptive Technology Award, one of laboratory medicine’s most competitive recognition programs. • Augurex will present at ADLM 2026 on July 27 in Anaheim, CA, with a dedicated finalist kiosk on the Expo Floor July 28–30. • The recognition underscores Augurex’s leadership in developing biomarker-driven diagnostics that address critical unmet needs across autoimmune and inflammatory diseases.
May 28, 2026
·
1 min read
Biotech Bay
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research
Invivoscribe and Complete Genomics announced that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics’ NGS platforms.
June 2, 2023
·
3 min read
Policy
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay
We are pleased to announce that Invivoscribe’s LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI and the EMA as a Class C CDx assay, meeting the stringent new IVDR 2017/746) requirements.
May 11, 2023
·
4 min read
Press Releases
Medical Care Technologies Inc. (OTC Pink:MDCE) Expands AI Commercialization Strategy with Enterprise Vision Solutions
May 11, 2026
·
2 min read
1 of 63,453
Next
